Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 3.255 USD 8.5% Market Closed
Market Cap: 232m USD
Have any thoughts about
Zentalis Pharmaceuticals Inc?
Write Note

Zentalis Pharmaceuticals Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zentalis Pharmaceuticals Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Free Cash Flow
-$208.4m
CAGR 3-Years
-34%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$15.6B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$10B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$6.3B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
-$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.3B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
20%
No Stocks Found

Zentalis Pharmaceuticals Inc
Glance View

Market Cap
231.6m USD
Industry
Biotechnology

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

ZNTL Intrinsic Value
2.773 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Zentalis Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-208.4m USD

Based on the financial report for Dec 31, 2023, Zentalis Pharmaceuticals Inc's Free Cash Flow amounts to -208.4m USD.

What is Zentalis Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-53%

Over the last year, the Free Cash Flow growth was -25%. The average annual Free Cash Flow growth rates for Zentalis Pharmaceuticals Inc have been -34% over the past three years , -53% over the past five years .

Back to Top